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e-mail address: Algarui@yahoo.comAlberto Galvez-RuizAbstractDominant optic atrophy (DOA) and Wolfram syndrome share a great deal of clinical variability, including an association with hear-
ing loss and the presence of optic atrophy at similar ages. The objective of this paper was to discuss the phenotypic variability of
these syndromes with respect to the presentation of two clinical cases.
We present two patients, each with either DOA or Wolfram syndrome, and contribute to the research literature through our
findings of two novel mutations.
The overlapping of several clinical characteristics in hereditary optic neuropathies can complicate the differential diagnosis. Future
studies are needed to better determine the genotype-phenotype correlation for these diseases.
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In hereditary optic neuropathies, the differential diagno-
sis is broad. However, Dominant Optic Atrophy (DOA) and
Wolfram syndrome (WS) share significant clinical variability,
including an association with hearing loss and the pres-
ence of optic atrophy at similar ages (first decade of
life).1–3
We present two cases of patients with either DOA or WS,
and we contribute to the research literature through our find-
ings of two novel mutations.
The objective of this work was to comment on the pheno-
typic variability of these syndromes with respect to the pre-
sentation of two clinical cases.Case reports
Patient 1
Female patient, 25 years of age with refractive error since
puberty (average myopia in both eyes) (OU) admitted to the
hospital for possible refractive surgery.
Upon pre-surgery evaluation, bilateral temporal papillary pal-
lor is detected, so the patient is referred to the Neuro-ophthal-
mology unit for study. The patient has no family history of
vision loss and does not present with hearing loss or any other
neurological symptom. There is a family history of consanguinity.
On ophthalmic examination, the patient presents a visual
acuity (VA) of 0 (logMAR units) OU with correction. Thee:
al.com
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with OU. The pupils are isochoric, normoreactive to light
and accommodation, and no relative afferent pupillary defect
(RAPD) is detected. The ocular fundus shows a congenitally
anomalous papilla with temporal pallor in OU (Fig. 1).
Optical coherence tomography (OCT) of the optic nerve
(RTVue Premier Optovue) performed for the patient showed
a reduction mainly in the temporal portion of the retinal
nerve fiber layer (RNFL) thickness in OU (Fig. 2).
Magnetic resonance imaging (MRI) of the skull base and
orbits is normal. The Humphrey visual field (HVF) testing
(SITA-fast 30-2) shows a normal result in the OD (mean devi-
ation 0.96 dB) and some isolated scotomas in the OS (mean
deviation 3.01 dB). The result for the OS may be unreliable
due to the excess of false positives (Fig. 3). The genetic
analysis requested shows that the patient is a heterozygous
carrier of the missense mutation p.Tyr917His (c.2749T > C)
in the optic atrophy 1 (OPA1) gene, which is diagnostic for
DOA. The result was confirmed by sequencing of an indepen-
dent PCR product (polymerase chain reaction). Also, two
bioinformatics tools conducted predicted a pathogenic
character for this mutation. To our knowledge, this mutation
has not been described previously in the literature. After over
a year of follow-up, the patient has remained clinically stable.
Patient 2
Female patient, 20 years old, comes to the office following
a neuro-ophthalmology consultation after presenting with
decreasing VA since childhood. The patient was also diag-
nosed with diabetes mellitus (DM) at 3 years of age. The
patient does not present with hearing loss or any other asso-
ciated neurological symptoms or show signs or symptoms of
diabetes insipidus (DI). The patient has no family history of
vision loss, although there is a family history of consanguinity.
On ophthalmic examination, the patient has a VA of +1.0
(logMAR) in the right eye (OD) and of +1.6 (logMAR) in the
left eye (OS). The pupils are isochoric, normoreactive to light
and accommodation and without RAPD. The fundus shows
bilateral temporal pallor with normal maculae in OU
(Fig. 4). The GVF demonstrates the existence of a bilateral
cecocentral defect. Cranial MRI of the orbits is normal. The
patient presents normal plasma and urine osmolalities. The
genetic study requested shows that the patient is homozy-
gous for the c.1046_1047delinsAG p.lle349Lys mutation in
exon 8 of the Wolfram syndrome 1 (WFS1) gene, which is
diagnostic for WS. To our knowledge, this variant has notFigure 1. Fundus of patient 1 showing congenitallybeen described previously. Also we conducted OPA1, OPA3
and OPA7 genetic tests for the patient, resulting all of them
negative. After over a year of follow-up, the patient has
remained clinically stable without the onset of new symptoms.
Discussion
In the present article, we report two clinical cases of
hereditary optic neuropathy: a patient diagnosed with DOA
carrying a novel mutation in the OPA1 gene but with virtually
no visual symptoms; and another patient diagnosed with WS
due to a novel mutation in the WFS1 gene but without
deafness or DI. Both patients show significant clinical
variability in these entities, presenting with phenotypically
atypical or incomplete clinical cases.
DOA typically manifests as the insidious loss of VA in the
first decade of life.1,4 On ophthalmic examination, pallor of
the temporal sector of the optic nerve is demonstrated with
excavation that can simulate glaucoma.1,5 On visual field test-
ing, central or cecocentral scotomata are characteristic.1,6
There are also patients with a phenotype designated DOA
plus, which can be associated with sensorineural hearing loss,
myopathy, peripheral neuropathy, ataxia, symptoms that
mimic multiple sclerosis and spastic paraplegia.1,7
The majority of DOA cases are caused by mutations in the
OPA1 gene (50–60% of patients). Specifically, more than 200
pathogenic mutations have been described in the OPA-1
gene. However, in large-scale studies, some families with
DOA have had mutations associated with other chromosomal
loci: OPA-3, OPA-4, OPA-5, and OPA-7,8–10
The OPA1 gene encodes a protein (dynamin-related
GTPase) of the inner mitochondrial membrane. Its absence
or dysfunction results in an alteration in the mitochondrial
DNA stability as well as the integrity of the mitochondrial res-
piratory chain.11
One of the main clinical characteristics of DOA is its great
clinical variability: there are patients with isolated visual
repercussions (such as the patient we present here) while
others experience legal blindness; there are clinical presenta-
tions that exclusively affect the optical nerve, and there are
syndromic forms with multiple neurological symptoms (20%
of all patients). This interfamilial and intrafamilial phenotype
variability is explained in part by the different degrees of
penetration of DOA, which has been calculated to be
approximately 70%.1 However, it is also due to the presence
of mitochondrial DNA deletions caused by nuclear mutations
in the OPA1 gene. Thus, DOA is considered a mitochondrialanomalous papilla with temporal pallor in OU.
Figure 2. Optical coherence tomography (OCT) of the optic nerve (RTVue Premier Optovue) showing a reduction mainly in the temporal portion of the
retinal nerve fiber layer (RNFL) thickness in OU. The mean RNFL average for the OD was 71 lm and for the OS 68 lm (A). We include also the Ganglion
Cell complex thickness analysis (B), which is reduced in OU (Average thickness Ganglion cell complex OD: 62 lm and OS: 56 lm).
Figure 3. Humphrey visual field (HVF) testing (SITA-fast 30-2) showing a normal result in the OD (mean deviation 0.96 dB) and some isolated scotomas
in the OS (mean deviation 3.01 dB). The result for the OS may be unreliable due to the excess of false positives.
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chondrial syndromes.1
The case of our patient with virtually no visual symptoms
and with incipient optic nerve pallor is one of the mildest
extremes on the spectrum of presentation of DOA.
Normally, this type of virtually asymptomatic patient is
discovered when performing a genetic analysis on the
relatives of a patient with DOA. In our patient, the diagnosis
was suspected when the optic nerve pallor was discovered on
workup prior to refractive surgery.Regarding WS, in its original description, DM and optic
atrophy that are present from an early age in life are
mentioned as characteristics. In later descriptions, the
presence of DI and hearing loss was added.12 Thus, this
syndrome is also known by the acronym DIDMOAD (diabetes
insipidus, diabetes mellitus, optic atrophy and deafness).
Approximately 50% of patients present with the complete
phenotype.
DM and optic atrophy have an average age of onset of
10 years. Hearing loss is present in 66% of individuals with
Figure 4. Fundus of patient 2 showing bilateral temporal pallor with normal maculae in OU.
310 A. Galvez-Ruizan average age of onset of 12.5 years. DI occurs in 72% of
individuals with an average age of onset of 15.5 years.
Other neurological alterations that may be present in these
individuals include ataxia, apnea, dementia and psychiatric
disorders.13
In 1997, the WSF1 gene was identified in the 4p16.1
region. The majority of mutations in patients with WS are
inherited recessively and are located in exon 8, but mutations
have also been described in exons 3, 4, and 5.13
The WFS1 is a transmembrane protein of the endoplasmic
reticulum (ER). This organ controls the folding of cellular pro-
teins. Under physiological conditions, the accumulation of
unfolded proteins provokes WFS1 to stop translating
proteins, activating the chaperones responsible for protein
folding. However, if the accumulation of unfolded proteins
persists (as is the case in WFS1 deficiency), cell apoptosis is
induced.14
Mutations in the WFS1 gene are responsible for a wide
phenotypic spectrum: in addition to classic WS, they have
been described as WS-like (associated with deafness, DM,
psychiatric alterations and in some cases, optic atrophy)1
and the syndrome of sensorineural deafness associated with
WFS1 that presents in isolation. Also, WS type 2 has recently
been described in 4 Jordanian families, characterized by
optic atrophy, DM and deafness but not DI. It is caused by
mutations in the CDGSH iron sulfur domain 2 (CISD2) gene
(located on chromosome 4q22).1
Interestingly, similar to patients with OPA1 mutations,
deletions in mitochondrial DNA have been described in
WS. This finding perhaps also explains the great variability
in clinical expression present in WS, which is similar to the
wide phenotypic spectrum of diseases of mitochondrial
origin.1
Our patient with WS, despite having an age of 20 years,
presents only part of the clinical spectrum of the syndrome
(DM diagnosed at 3 years and optic atrophy). It should be
considered that the mutation the patient carries (causing
changes in a single amino acid) likely entails a more benign
phenotype expression. However, it is necessary to follow
the patient for years to determine definitive clinical
expression.
In summary, we present the cases of two patients each car-
rying novel mutations in either the OPA1 or WSF1 genes that
represent good examples of the significant intra- and interfa-
milial clinical variability that can occur in hereditary optic neu-
ropathies. This variability is due in part to the differentmutations in the OPA1 and WFS1 genes and to their different
degrees of penetration. However, the fact that both muta-
tions are in some cases related to mitochondrial DNA dele-
tions potentially partially explains this variability. However,
there is no complete scientific explanation at present for this
variability, and future research will be needed to continue to
clarify its source.
Similarly, the overlap between certain clinical characteris-
tics in several of these syndromes (such as optic atrophy
and hearing loss) delays diagnosis in some patients (espe-
cially in patients with phenotypes that vary from the classical
presentations).
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